secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-11-10T21:36:23+00:00
Accession:  0001420720-26-000035
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

iBio Q1 FY2027 revenue rises to $1.1M; IBIO-600 SAD dosing complete, IBIO-610 IND due end-2026
--------------------------------------------------------------------------------

- Revenue of ~$1.1M vs $0.1M a year earlier; R&D $6.7M (+87% YoY) on IBIO-600 Phase 1, NHP studies and CMC; G&A $2.8M (+10%).
- Cash, cash equivalents and investments in debt securities totaled ~$76.7M as of September 30, 2026.
- IBIO-610 NHP data at EASD: fat was 93% of weight lost with semaglutide combo vs 77% for semaglutide alone; lean mass 6% vs 22%.
- IBIO-600 Phase 1 single ascending dose dosing complete; interim SAD data and start of multiple ascending dose portion expected in Q1 2027.
- iBio targets an IND-equivalent filing for IBIO-610 by end of 2026 and first-in-human studies in the first half of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000035/0001420720-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000035/ibio-20261110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer